DaxibotulinimtoxinA for Treatment of Platysmal Neck Bands

Aging Clinical Trial

Official title:

Use of DaxibotulinimtoxinA Injection for Platysma Bands of the Neck

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06225492
• Other study ID #: DAXI0823
• Status: Recruiting
• Phase: Phase 4
• Start date: January 1, 2024
• Est. completion date: January 1, 2026

Study information

• Verified date: January 2024
• Source: Main Line Center for Laser Surgery
• Contact: Jessica Plugis
• Phone: 610-645-5551
• Email: jess[@]dermguy.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study seeks to evaluate the effectiveness and duration of action of DaxibotulinumtoxinA for neck rejuvenation through treatment of platysmal bands. This study will consist of one treatment visit with subjects being randomized to receiving 15 or 20 units of DaxibotulinumtoxinA per platysmal band. Subjects will return for 5 follow-up visits at 8, 12, 16, 20, and 24 weeks for evaluation.

Description:

This clinical investigation is a prospective study consisting of a screening/treatment visit and 5 follow-up visits. A total of 20 patients will be recruited.

Following informed consent and screening, each eligible subject will be photographed. Next, patients will be randomized to receive 15 or 20 units of DaxibotulinumtoxinA per platysmal band. Patients randomized to each group will receive the same dosage injected to each neck band divided over 4 to 5 injection sites (up to 2 anterior and 2 lateral platysmal bands).

After randomization, patients will be treated with either 15 or 20 units per band. After treatment, subjects will be provided with post treatment instructions. Randomization will be conducted by having the patient pick either "15" or "20" out of a box. A total of 10 patients will be randomized to the 15 unit/platysmal band group. Another 10 patients will be randomized to the 20 unit/platysmal band group. The physician will fill out the 5-point Merz Neck Scale at baseline and at each follow-up visit. Photographs will be captured at each visit.

The patient will return at post-treatment weeks 8, 12, 16, 20, and 24. Subjects will fill out FACE-Q Satisfaction with Outcome surveys at each follow-up visit. FACE-Q Appraisal of Neck surveys will be filled out by the patient at the baseline and follow-up visits.

A blinded independent evaluator will evaluate the baseline and post-treatment photographs on Merz Neck Scale after completion of the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: January 1, 2026
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 31 Years and older

Eligibility

Inclusion Criteria:

• >30 years old

• Rating of 2, 3, or 4 on 5-point Merz Neck Scale

• No use of any botulinum toxin in the neck for the past 6 months

Exclusion Criteria:

• Pregnancy

• Prior adverse reaction or known hypersensitivity to neuromodulators treatment

• Connective tissue disorder

• Scar in the treatment area

• History of dysphagia and/or neuromuscular disorders (such as but not limited to Amyotrophic Lateral Sclerosis, Multiple sclerosis, Myasthenia Gravis, Lambert-Eaton syndrome, others per PI's discretion)

• Active infection in treatment area

• Active moderate or severe inflammatory disease in treatment area such as atopic dermatitis, psoriasis

• Prior treatment with neuromodulators in treatment area (neck) within the past 6 months

Related Conditions & MeSH terms

• Aging

Intervention

Drug:
• DaxibotulinumtoxinA 15 units
Subjects will be treated with 15 units of daxibotulinumtoxinA per platysmal band
• DaxibotulinumtoxinA 20 units
Subjects will be treated with 20 units of daxibotulinumtoxinA per platysmal band

Locations

Country	Name	City	State
United States	Main Line Center for Laser Surgery	Ardmore	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Main Line Center for Laser Surgery

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effectiveness of DaxibotulinumtoxinA for platysmal neck bands measured on Platysmal Neck Banding Scale	Platysmal Neck Banding Scale (Scored on a 1-5 scale with 5 being the most severe)	12 months
Secondary	Evaluate patient-reported outcomes (patient satisfaction with neck using FACE-Q scale)	Patient satisfaction with neck using FACE-Q scale (scored on a 1-100 scale with 100 being highest satisfaction)	12 months